Kathy Reape

Kathy Reape began their career in the pharmaceutical industry in 2000 as a Director of Medical Affairs at Wyeth Pharmaceuticals. In 2003, they joined Duramed Research as VP of Clinical Development and Medical Affairs. Duramed was a subsidiary of Barr Pharmaceuticals at the time. Reape remained in this role until 2009 when they left to join Teva Pharmaceuticals as VP of Women's Health Research and Development. Kathy stayed with Teva until 2011 when they left to join Actavis, Inc. as VP of Medical Affairs and Women's Health Clinical Research. In 2014, Actavis was acquired by Allergan and Reape became SVP of Clinical Development for Global Brands R&D. Kathy held this role until 2015 when they left to join Spark Therapeutics, Inc. as Chief Medical Officer. Reape stayed with Spark until 2020 when they left to become Director at Taysha Gene Therapies, their current role.

Kathy Reape has a BA in Biology from the University of Pennsylvania and an MD from the University of Pennsylvania School of Medicine. Kathy completed their residency in Obstetrics/Gynecology at Rutgers Robert Wood Johnson Medical School.